Trump's New Deal on Drugs: Reducing Health Care Burdens and Deregulation Become Important Journeys

Make America Great Again (MAGA) and America First are the core values of Trump's New Deal. In order to consolidate U.S. economic hegemony, it is widely expected that Trump's New Deal will use the U.S. Federal Reserve's Fed to implement a weak U.S. dollar to create a quantitative easing environment of currency depreciation and low interest rates; massive corporate tax cuts. The large-scale corporate tax cuts will reduce the corporate tax rate from 21% to 15% to reduce the operating burden on U.S. businesses, and the trade tariffs will be wielded to expand trade barriers by imposing 10-20% tariffs on imported goods, while Chinese goods will be subjected to up to 60% tariffs. Through the depreciation of the U.S. dollar, corporate tax cuts and tariff increases to enhance the export competitiveness of the U.S. manufacturing industry and promote the return of manufacturing industry, and low-interest rate environment will also help U.S. companies to acquire overseas assets, in this context, Trump's new policy on the pharmaceutical industry will bring what development trends and impact?